

## All Studies:

- An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of XXXX in the Treatment of Children and Adolescents with Major Depressive Disorder, 2007 to present
- A Double-Blind Study of XXXX versus Placebo for the Treatment of ADHD in Young Adults with an Assessment of Associated Functional Outcomes, 2007 to present
- A Parallel, Randomized, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Trial to Assess the Efficacy and Safety of 2 Different Transdermal Doses of XXXX in Subjects with Signs and Symptoms Associated with Fibromyalgia Syndrome, 2007 to present
- Fixed Dose Comparison of XXXX to an Active Comparator in Severely Depressed Patients, 2006 to present
- An Open-Label, Behavioral-Treatment-Controlled Evaluation of the Effects of XXXX on the Frequency of Cytogenetic Abnormalities in Children 6-12 years of Age with ADHD, 2006 to 2007
- An Eight-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with Escitalopram as an Active Control, to Evaluate the Efficacy, Safety, and Tolerability of a XXXX mg Dose Once Daily, in Patients with Generalized Anxiety Disorder, 2006 to present
- A 9-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Efficacy and Safety of XXXX as Treatment for Adults with Attention Deficit/Hyperactivity Disorder, 2006 to 2007
- A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of XXXX in Adults with Attention-Deficit Hyperactivity Disorder, 2006 to 2007
- A Long-Term, Open-Label, and Single-Arm Study of XXXX Per Day in Adults with Attention-Deficit Hyperactivity Disorder, 2006-to present
- A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Sustained-release XXXX Compared with Placebo in the Treatment of Generalized Anxiety Disorder, 2006 to present
- A Comparison Of XXXX Extended-Release Vs. Placebo In The Treatment Of Insomnia Associated With Generalized Anxiety Disorder (GAD) When Used Concomitantly With Escitalopram, 2006 to 2007
- A Comparison Of XXXX Extended-Release Vs. Placebo In The Treatment Of Insomnia Associated With Newly Diagnosed Major Depressive Disorder (MDD) Or Untreated MDD Relapse, When Used Concomitantly With Escitalopram, 2006 to 2007
- A Multi-center, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of XXXX as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period, 2005 to 2007
- A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of XXXX Twice Daily in Patients with Fibromyalgia, 2005 to 2006
- A 12-Week, Open-Label, Safety Trial of XXXX in patients with Fibromyalgia, 2005 to 2006
- Dose Response Study of XXXX Versus Placebo in the Treatment of Fibromyalgia Syndrome, 2005 to 2007
- A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy and Safety of XXXX Versus Placebo in Adults with Attention Deficit Hyperactivity Disorder, 2005 to 2006

A Phase III, Multi-center, 12-month, Open-label Safety Study of XXXX in Adults with Attention-Deficit Hyperactivity Disorder (ADHD), 2005 to 2006

A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-group, Forced Dose Titration, Safety and Efficacy Study of XXXX in Adults with Attention-Deficit Hyperactivity Disorder (ADHD), 2005

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder, 2005 to 2006

A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of XXXX as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder, 2005 to present

XXXX Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder, 2004 to 2007

Eight-Week, Double-Blind, 3-Arm Parallel, Placebo-Controlled, Randomized Efficacy and Safety Trial of XXXX, XXXX plus YYYY, and Placebo in Adults with Attention Deficit Hyperactivity Disorder, 2004 to 2005

A Phase III, Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel-Group, Safety and Efficacy Study of XXXX in Adults with Attention Deficit Hyperactivity Disorder (ADHD), 2004 to 2005

A 13-Week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of XXXX in Patients with Fibromyalgia, 2004 to 2005

A Long-Term, Open Label, Safety Trial of XXXX in Patients with Fibromyalgia, 2004 to present

A Double-Blind Study of Functional Outcomes with XXXX and Placebo in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2003 to 2005

XXXX Versus Lamotrigine in the Treatment of Bipolar I Depression, 2003 to 2004

Evaluation of Continuous Symptom Treatment of ADHD: A Placebo-Controlled Double-Blind Assessment of Morning-Dosed or Evening-Dosed XXXX, 2003 to 2004

A 7-Month, Multi-center, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of XXXXX and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8-week Observational Follow-up Phase, 2003 to 2004

Open-Label XXXXX Compassionate Use in Patients Who Have Completed a Previous Neuroscience XXXXX Clinical Trial, 2003 to 2004

A Phase III, Multi-center, 24-month, Open-label Safety, Tolerability and Efficacy Study of XXXX in the Treatment of Adolescents Aged 13-18 with Attention Deficit Hyperactivity Disorder (ADHD), 2003 to 2006

A Phase III, Randomized, Multi-Center, Double-Blind, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of XXXXX in Adolescents Aged 13-17 with Attention Deficit Hyperactivity Disorder (ADHD), 2003 to 2004

A Phase II Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy, Safety and Tolerability of Two Doses (20 mg and 60mg) of a Once-Daily Oral Formulation of XXXXX in Subjects with Major Depressive Disorder for a Treatment Period of Eight Weeks, 2003

A Phase IIA Double-Blind, Multicenter, Placebo-Controlled Study of XXXX Versus Lorazepam in the Treatment of Outpatients With Generalized Anxiety Disorder, 2002 to 2003

XXXX versus Placebo in the Treatment of Fibromyalgia Patients With or Without Major Depressive Disorder, 2002 to 2003

A 6-1/2 Month, Multicenter, Randomized, Double-blind, Placebo-Controlled Comparison of XXXX and Placebo for the Prevention of Seasonal Affective Disorder in Subjects with a History of Seasonal Affective Disorder, 2002 to 2003

A Double-Blind, Multicenter, Placebo-Controlled Study of XXXX in the treatment of Patients With Major Depressive Disorder, 2002 to 2003

A Double-Blind Study of Treatment Optimization with XXXX in Adults with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2002 to 2003

A Multicenter Study of XXXX Once-Daily Dosing Versus Placebo in Patients with Major Depression and Pain, 2002

A Randomized, Double-Blind, Placebo-Controlled Trial of XXXX to Evaluate Efficacy in the Treatment of Attention-Deficit/Hyperactivity Disorder in Children Ages 6-12 with an Assessment of Evening Behavior, 2002 to 2003

A Phase 4, Double-Blind, Placebo-Controlled Trial Of XXXX To Evaluate Efficacy In The School Setting In Children Ages 8 To 12 Years With Attention-Deficit/Hyperactivity Disorder, 2001 to 2003

A Seven-week, Double-Blind, Extension of Protocol YYYY: A Phase IIB, Seven-Week, Double-Blind, Placebo- And Paroxetine-Controlled Multicenter Study To Evaluate The Safety And Efficacy Of XXXX In Outpatients With Major Depressive Disorder And Associated Somatic Symptoms, 2001 to 2002

A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial To Evaluate The Efficacy And Tolerability Of XXXX In Patients With Generalized Anxiety Disorder (GAD), 2001 to 2002

A Phase IIB, Seven-Week, Double-Blind, Placebo- And Paroxetine-Controlled Multicenter Study To Evaluate The Safety And Efficacy Of XXXX In Outpatients With Major Depressive Disorder And Associated Somatic Symptoms, 2001 to 2002

A Double-Blind, Placebo Controlled, Fixed-Dosage Study Comparing The Efficacy And Tolerability Of XXXX And Citalopram To Placebo In The Treatment Of Major Depressive Disorder With Anxiety, 2001

Long-Term Open-Label Safety Study of XXXX in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2000 to 2005

A Multicenter Phase III Randomized, Double-Blind Comparison of Placebo and XXXX in Adult Outpatients with DSM-IV Attention-Deficit/Hyperactivity Disorder, 2000-2001

A Multicenter Study of XXXX Versus Placebo and Paroxetine in the Acute Treatment of Major Depression, 2000-2001

A Multicenter Study of XXXX Versus Placebo in the Treatment of Generalized Anxiety Disorder; 1999-2000

A Multicenter Study of Long-Term Open-Label Treatment with XXXX Hydrochloride for Evaluation of Safety, 1999-2000

A Multicenter, Double-Blind, Placebo-Controlled Comparison of the Safety and Efficacy and Effects on Sexual Functioning of XXXX and Fluoxetine in Outpatients with Moderate to Severe Recurrent Major Depression, 1999-2000

A Randomized, Double-Blind, Placebo-Controlled, Flexible Dosage Trial to Evaluate the Efficacy and Tolerability of XXXX in Patients with Generalized Anxiety Disorder, 1999

A Multicenter, Randomized, Double-Blind, Fixed Dose Comparison of XXXX and Placebo in Patients Suffering from Posttraumatic Stress Disorder, 1998-1999

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of XXXX Versus Placebo in Panic Disorder, 1998-2000

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of XXXX in the Treatment of Attention Deficit/Hyperactivity Disorder in Adults, 1998

An Open-Label, Long-Term, Safety Study of XXXX in the Treatment of Anxious Outpatients, 1997-1998

A Multicenter, Double-blind, Randomized, Placebo-controlled Evaluation of XXXX Efficacy at Early Time Points in the Acute Treatment of Migraine Headaches, Efficacy in Recurrence,

and Efficacy as Late Dosing for Prevention of Recurrence of Migraine Headaches, 1997-1998